Managing Xylazine ("Tranq") Contamination in the Fentanyl Supply
A man’s unusually severe wound and unusually long, hard-to-rouse highs both point the same direction — a non-opioid sedative now widespread in the fentanyl supply that naloxone was never built to reverse.
The outreach nurse has known N.J. for over a year and considers him one of the more reliably good-humored regulars on her route — he comes to the street medicine van every couple of weeks, mostly, he says, for the coffee and the conversation rather than anything medical. He is thirty-nine, has been living outdoors under an overpass for the past several months after losing his apartment when the building was sold and converted, and used to work seasonal construction before a shoulder injury several years ago started the chain of events that eventually cost him his housing. He has injection opioid use disorder, primarily fentanyl, and a hepatitis C diagnosis he's never pursued treatment for, never quite finding the right window to start.
Today he came specifically because of his arm. A wound on his left forearm started as a small injection-site sore roughly three weeks ago and has grown into a deep, blackened ulcer with necrotic tissue at its base — far out of proportion to what he remembers as a normal injection complication from years of use, and visibly worse than anything he's shown the nurse before. He mentioned the arm first, almost as an aside, more focused on that than on himself, until the nurse asked him directly to describe what his last several highs had actually felt like. Only then did he say they had felt “different” — a heavier, longer sedation than fentanyl alone usually produces, with grogginess persisting for hours afterward. Twice recently he has woken up disoriented with no memory of the time in between, without the classic pinpoint-pupil, slowed-breathing picture he associates with a fentanyl overdose he's reversed with naloxone in others before, more than once, out here.
A wound and a sedation pattern that point to the same contaminant
This wound doesn't look like a typical injection-site abscess to me, and I don't think we should treat it like one. Xylazine-associated skin injury — deep, often disproportionate to the injection itself, sometimes appearing even at sites remote from where the drug was actually used — is now a well-documented, distinct pattern, described in DEA and CDC public health alerts tracking xylazine's spread through the fentanyl supply. I'd manage this as debridement-focused wound care with that specific mechanism in mind, not just standard cellulitis treatment.
I want to make sure we're equally direct with him about the sedation pattern, because there's a genuinely dangerous misunderstanding at stake. Xylazine is not an opioid — it's an alpha-2-adrenergic sedative, and naloxone does not reverse its effects at all. If we don't explain that clearly, he could reasonably conclude the naloxone he's used before has "stopped working" or that his fentanyl has become naloxone-resistant, when what's actually happening is a second, non-opioid sedative riding along in the same supply.
The wound care matters, but if he walks out of here without understanding that distinction, the next time someone finds him unresponsive, he or a bystander might reasonably but wrongly decide naloxone isn't worth trying — and that's the more immediately dangerous gap.
Both are right, and I don't think we need to choose which to address first — they're the same underlying problem. I'd start wound care today, here, without requiring he stop using or come inside for it, and pair it with direct counseling: naloxone should still always be given for a suspected overdose, since most of the supply remains fentanyl-predominant and xylazine rarely appears alone, but recovery may take longer and breathing support or calling 911 matters more, not less, when xylazine is likely involved.
Agreed: wound care started today at the van, additional naloxone supplied, and direct counseling given on xylazine's non-opioid mechanism and why naloxone still matters despite it.
Not agreed: whether the street medicine team should proactively test supply samples for xylazine to give the broader outreach population more specific warnings, or whether individual patient counseling like today's is sufficient without that infrastructure. The toxicologist supports pursuing local drug-checking resources given how much confusion the naloxone-response question creates; the harm reduction physician noted the team currently lacks funding or lab access for that and didn't want to promise something not yet available.